BFM
SGMO

Boothbay Fund Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Boothbay Fund Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-526
Closed -$566K – 888
2019
Q2 		$566K Buy
+526
New +$5.59K 0.05% 381

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Boothbay Fund Management's SGMO Position: Q1 2026 in Review

Boothbay Fund Management held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 277,311 shares worth $68.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1903.

Boothbay Fund Management first reported a position in SGMO in Q2 2018 and has held it in 8 quarters since. The position peaked at $548K in Q4 2024. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Boothbay Fund Management held 277,311 shares of SANGAMO THERAPEUTICS INC worth $68.5K as of Q1 2026.
  • Boothbay Fund Management left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1903 holding.
  • Boothbay Fund Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2018 and has held it in 8 quarters since.
  • Boothbay Fund Management's SANGAMO THERAPEUTICS INC position peaked at $548K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.